The case underscores the challenges in managing PV, particularly in young patients, and highlights the potential clinical significance of additional <i>JAK2</i> mutations/variants and the potential benefits of Ropeginterferon alfa-2b in achieving better disease control. This evidence concerns the gene JAK2 and acquired polycythemia vera.